Biotech Values

[srsmgja]

Additional case report of cancer in the Cladribine trial. This one developed 6 months after the trial completion. The tally thus far: 5 cancers in the Cladribine arms versus zero in the placebo arm.

This in a drug whose mechanism of action is to interfere with DNA replication and repair. This in a drug that is already associated with a cancer risk.

So who here believes that the FDA approves Cladribine with only one phase 3 trial and no additonal long term safety data?